You are here: Industry Insights > Starpharma

News List

Starpharma releases positive DEP® phase 2 interim results in prostate cancer prnasia
November 29, 2021
Melbourne biotech company Starpharma today announced positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel.
Australian biotech company Starpharma announces positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel prnasia
November 29, 2021
Starpharma showed that 100% of evaluable patients with Stage IV prostate cancer have had efficacy responses, utilising one or more standard measures of disease.
VIRALEZE SPL7013 virucidal (>99.99%) against Delta variant prnasia
July 28, 2021
Starpharma announced new data demonstrating that SPL7013, the antiviral agent in VIRALEZE™ nasal spray, is active against the highly transmissible Delta variant of SARS-CoV-2, achieving more than 99.99% reduction of infectious virus in ...
Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants prnasia
June 18, 2021
New data released today shows that Australia's Viraleze™ anti-COVID nasal spray is more than 99.9% effective against three of the four deadliest variants of the SARS-CoV-2 virus.
Viraleze registered for sale in Covid-ravaged India prnasia
June 11, 2021
India's vast population will have access from today to the Australian developed anti-COVID nasal spray Viraleze™ following its registration in the country.
Scripps Research Institute testing shows Viraleze highly active against UK COVID strain prnasia
June 02, 2021
Australia's Viraleze anti-COVID nasal spray is active against the highly infectious UK variant of SARS-CoV-2, the virus that causes COVID-19, reducing infectivity of the virus by >98%, it was announced today in a major development for the product.
Starpharma’s SPL7013 shows significant activity against SARS-CoV-2 pharmaceutical-business-review
April 22, 2020
Starpharma announced that its proprietary VivaGel active, astodrimer sodium (SPL7013), has been shown in laboratory studies to have significant antiviral activity against the coronavirus that causes COVID-19 (coronavirus disease).
Starpharma Signs Second Oncology Agreement with AstraZeneca americanpharmaceuticalreview
June 06, 2019
Starpharma announced a Development and Option Agreement with AstraZeneca to progress the development of a Dendrimer Enhanced Product (DEP®) version of an undisclosed AstraZeneca major marketed oncology medicine.
Mundipharma licenses Starpharma’s VivaGel BV biospectrumasia
May 03, 2018
Mundipharma will register and launch VivaGel BV as part of the popular BETADINE range, which is sold in more than 120 countries
Starpharma completes US New Drug Application for VivaGel BV biospectrumasia
May 02, 2018
VivaGel BV stands to be the first and only product approved for the prevention of recurrent BV

Previous page 1 2 Next page